- Home
- ALLE vs BMRN Comparison
ALLE vs BMRN Comparison
Compare ALLE & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | BMRN |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 13.0B |
| IPO Year | 2013 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ALLE | BMRN |
|---|---|---|
| Price | $156.40 | $64.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 18 |
| Target Price | ★ $167.13 | $88.22 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 3.74 | 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $8.47 | $15.02 |
| Revenue Next Year | $4.58 | $12.23 |
| P/E Ratio | ★ $42.01 | $86.40 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $125.00 | $49.26 |
| 52 Week High | $183.11 | $70.98 |
Technical Indicators
Market Signals| Indicator | ALLE | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 50.22 |
| Support Level | $139.95 | $64.07 |
| Resistance Level | $166.96 | $66.28 |
| Average True Range (ATR) | 3.69 | 1.60 |
| MACD | -1.25 | -0.36 |
| Stochastic Oscillator | 34.72 | 18.27 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.